Precision Oncology News

Immunomedics' Trodelvy Enters Phase II Triple-Negative Breast Cancer Trial in China

Nov 04, 2020

NEW YORK – Everest Medicines on Tuesday announced that the first patient in China had been dosed with sacituzumab govitecan (Immunomedic's Trodelvy) in a registration trial evaluating the treatment for metastatic triple-negative breast cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Immunomedics' Trodelvy Enters Phase II Triple-Negative Breast Cancer Trial in China

To read the full story....

Breaking News

AACR Study Tests Immunogenic Signature in Prostate Cancer Patients on Dual Checkpoint Inhibitor

Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement

In Brief This Week: Gilead Sciences, Atossa Therapeutics, Karmanos Cancer Institute

Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers

Portage Biotech Begins Phase I Trial of Invariant Natural Killer T-Cell Therapy

FDA Accepts IND for Arcellx's Multiple Myeloma Cell Therapy

Featured White Papers

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

What's Popular?

In Brief This Week: Gilead Sciences, Atossa Therapeutics, Karmanos Cancer Institute

Immunocore's Tebentafusp Prolongs Survival in Uveal Melanoma Patients, AACR Study Shows

With Support From Lawmakers, WGS Becoming More Accessible to Netherlands' Cancer Patients

Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement

Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers

Sponsorships